OBJECTIVES: Immunization with attenuated poxvirus-HIV-1 recombinants followed by protein boosting had protected four of eight rhesus macaques from HIV-2SBL6669 challenge. The present study was designed to confirm this result and to conduct the reciprocal cross-protection experiment. METHODS: Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only. Binding and neutralizing antibodies, cytotoxic T-lymphocytes (CTL) and CD8 T cell antiviral activity (CD8AA) were evaluated. One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669,. Protective outcome was assessed by monitoring virus isolation, proviral DNA and plasma viral RNA. RESULTS: Both immunization groups developed homologous binding antibodies; however, homologous neutralizing antibodies were only observed in NYVAC-HIV-2-immunized macaques. While no cross-reactive neutralizing antibodies were detected, both immunization groups displayed cross-reactive CTL. Significant CD8AA was observed for only one NYVAC-HIV-2-immunized macaque. Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques, although NYVAC-HIV-1 immunization resulted in significantly lower viral burdens compared with controls. CONCLUSIONS: Further delineation of cross-reactive mechanisms may aid in the development of a broadly protective vaccine.
OBJECTIVES: Immunization with attenuated poxvirus-HIV-1 recombinants followed by protein boosting had protected four of eight rhesus macaques from HIV-2SBL6669 challenge. The present study was designed to confirm this result and to conduct the reciprocal cross-protection experiment. METHODS: Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only. Binding and neutralizing antibodies, cytotoxic T-lymphocytes (CTL) and CD8 T cell antiviral activity (CD8AA) were evaluated. One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669,. Protective outcome was assessed by monitoring virus isolation, proviral DNA and plasma viral RNA. RESULTS: Both immunization groups developed homologous binding antibodies; however, homologous neutralizing antibodies were only observed in NYVAC-HIV-2-immunized macaques. While no cross-reactive neutralizing antibodies were detected, both immunization groups displayed cross-reactive CTL. Significant CD8AA was observed for only one NYVAC-HIV-2-immunized macaque. Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques, although NYVAC-HIV-1 immunization resulted in significantly lower viral burdens compared with controls. CONCLUSIONS: Further delineation of cross-reactive mechanisms may aid in the development of a broadly protective vaccine.
Authors: José Maria Marcelino; Pedro Borrego; Cheila Rocha; Helena Barroso; Alexandre Quintas; Carlos Novo; Nuno Taveira Journal: J Virol Date: 2010-09-15 Impact factor: 5.103
Authors: V Novitsky; N Rybak; M F McLane; P Gilbert; P Chigwedere; I Klein; S Gaolekwe; S Y Chang; T Peter; I Thior; T Ndung'u; F Vannberg; B T Foley; R Marlink; T H Lee; M Essex Journal: J Virol Date: 2001-10 Impact factor: 5.103
Authors: Jun Zhao; Joel Pinczewski; Victor R Gómez-Román; David Venzon; V S Kalyanaraman; Phillip D Markham; Kristine Aldrich; Matthew Moake; David C Montefiori; Yuanmei Lou; George N Pavlakis; Marjorie Robert-Guroff Journal: J Virol Date: 2003-08 Impact factor: 5.103
Authors: Kevin O Saunders; Sampa Santra; Robert Parks; Nicole L Yates; Laura L Sutherland; Richard M Scearce; Harikrishnan Balachandran; Todd Bradley; Derrick Goodman; Amanda Eaton; Sherry A Stanfield-Oakley; James Tartaglia; Sanjay Phogat; Giuseppe Pantaleo; Mariano Esteban; Carmen E Gomez; Beatriz Perdiguero; Bertram Jacobs; Karen Kibler; Bette Korber; David C Montefiori; Guido Ferrari; Nathan Vandergrift; Hua-Xin Liao; Georgia D Tomaras; Barton F Haynes Journal: J Virol Date: 2018-03-28 Impact factor: 6.549
Authors: Carmen Elena Gómez; Beatriz Perdiguero; Cristina Sánchez-Corzo; Carlos Oscar S Sorzano; Mariano Esteban Journal: Viruses Date: 2017-12-27 Impact factor: 5.048
Authors: Giacomo Gorini; Slim Fourati; Monica Vaccari; Mohammad Arif Rahman; Shari N Gordon; Dallas R Brown; Lynn Law; Jean Chang; Richard Green; Fredrik Barrenäs; Namal P M Liyanage; Melvin N Doster; Luca Schifanella; Massimiliano Bissa; Isabela Silva de Castro; Robyn Washington-Parks; Veronica Galli; Deborah H Fuller; Sampa Santra; Michael Agy; Ranajit Pal; Robert E Palermo; Georgia D Tomaras; Xiaoying Shen; Celia C LaBranche; David C Montefiori; David J Venzon; Hung V Trinh; Mangala Rao; Michael Gale; Rafick P Sekaly; Genoveffa Franchini Journal: PLoS Pathog Date: 2020-03-12 Impact factor: 6.823